Join the Oncology Voice Network. Join for Free
All About Thought Leader Liaison
Thought Leader Engagement Pharma Industry Key Opinion Leaders Strategic Relationships Healthcare Professionals

All About Thought Leader Liaison


Share This Article


Summary

This weeks guest is Jim Hahn, Senior Business Director, Thought Leader Engagement at EMD Serono who discusses the role of the Thought Leader Liaison and how it fits into the pharma world.

Key Points

  • Thought leader liaisons (TLLs) focus on building deep, strategic relationships with key opinion leaders (KOLs) to align commercial objectives with the needs of healthcare providers.
  • TLLs typically come from successful sales backgrounds and do not require advanced scientific degrees, but must have strong interpersonal skills and a thorough understanding of their therapeutic area.
  • Effective communication between TLLs, MSLs, and sales reps is crucial to ensure seamless interactions with healthcare professionals and to avoid conflicts over access and time.

This weeks guest is Jim Hahn, Senior Business Director, Thought Leader Engagement at EMD Serono who discusses the role of the Thought Leader Liaison and how it fits into the pharma world.

Click for Source
Thought Leader Engagement, Pharma Industry, Key Opinion Leaders, Strategic Relationships, Healthcare Professionals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Podcast
How Should Medical Affairs Engage on Social Media
Partner Avatar MSL Talk: Tom Caravela

How Should Medical Affairs Engage on Social Media

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Explore OVN